image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 65.56
1.39 %
$ 1.42 B
Market Cap
-55.56
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ANIP stock under the worst case scenario is HIDDEN Compared to the current market price of 65.6 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ANIP stock under the base case scenario is HIDDEN Compared to the current market price of 65.6 USD, ANI Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one ANIP stock under the best case scenario is HIDDEN Compared to the current market price of 65.6 USD, ANI Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIP

image
$74.0$74.0$72.0$72.0$70.0$70.0$68.0$68.0$66.0$66.0$64.0$64.0$62.0$62.0$60.0$60.0$58.0$58.0$56.0$56.0$54.0$54.0$52.0$52.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
614 M REVENUE
26.20%
584 K OPERATING INCOME
-98.76%
-18.5 M NET INCOME
-98.63%
64 M OPERATING CASH FLOW
-46.19%
-405 M INVESTING CASH FLOW
-2086.37%
265 M FINANCING CASH FLOW
292.87%
197 M REVENUE
3.44%
26.2 M OPERATING INCOME
698.31%
15.7 M NET INCOME
252.60%
35 M OPERATING CASH FLOW
120.62%
-19.8 M INVESTING CASH FLOW
-85.81%
-9.91 M FINANCING CASH FLOW
-101.87%
Balance Sheet ANI Pharmaceuticals, Inc.
image
Current Assets 528 M
Cash & Short-Term Investments 151 M
Receivables 222 M
Other Current Assets 155 M
Non-Current Assets 756 M
Long-Term Investments 0
PP&E 56.9 M
Other Non-Current Assets 699 M
11.78 %17.27 %12.06 %4.43 %54.46 %Total Assets$1.3b
Current Liabilities 194 M
Accounts Payable 45.7 M
Short-Term Debt 9.17 M
Other Current Liabilities 139 M
Non-Current Liabilities 661 M
Long-Term Debt 615 M
Other Non-Current Liabilities 46.6 M
5.34 %16.24 %71.91 %5.45 %Total Liabilities$855.2m
EFFICIENCY
Earnings Waterfall ANI Pharmaceuticals, Inc.
image
Revenue 614 M
Cost Of Revenue 250 M
Gross Profit 364 M
Operating Expenses 364 M
Operating Income 584 K
Other Expenses 19.1 M
Net Income -18.5 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)614m(250m)364m(364m)584k(19m)(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.27% GROSS MARGIN
59.27%
0.10% OPERATING MARGIN
0.10%
-3.01% NET MARGIN
-3.01%
-4.32% ROE
-4.32%
-1.44% ROA
-1.44%
0.04% ROIC
0.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ANI Pharmaceuticals, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.5 M
Depreciation & Amortization 67.7 M
Capital Expenditures -17 M
Stock-Based Compensation 29.3 M
Change in Working Capital -11.2 M
Others 18.6 M
Free Cash Flow 47.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ANI Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ANIP of $76.3 , with forecasts ranging from a low of $60 to a high of $86 .
ANIP Lowest Price Target Wall Street Target
60 USD -8.48%
ANIP Average Price Target Wall Street Target
76.3 USD 16.43%
ANIP Highest Price Target Wall Street Target
86 USD 31.18%
Price
Max Price Target
Min Price Target
Average Price Target
909085858080757570706565606055555050Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership ANI Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
426 K USD 4
3-6 MONTHS
636 K USD 3
6-9 MONTHS
2.84 M USD 5
9-12 MONTHS
6.36 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
ANI Pharmaceuticals Announces Presentation of New Preclinical Data The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress globenewswire.com - 2 weeks ago
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: globenewswire.com - 4 weeks ago
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of  acute gout flares Trial to be conducted by Dr. Hyon Choi at Massachusetts General Hospital and will compare the safety and efficacy of two dose levels of Purified Cortrophin Gel for the treatment of acute gout flares PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the initiation of a Phase 4 clinical trial at Massachusetts General Hospital to compare the safety and efficacy of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for the treatment of acute gout flares. globenewswire.com - 1 month ago
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: globenewswire.com - 1 month ago
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com - 1 month ago
ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by. seekingalpha.com - 1 month ago
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. zacks.com - 1 month ago
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago. zacks.com - 1 month ago
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025. globenewswire.com - 1 month ago
ANI Pharmaceuticals: A Short-Term Buying Opportunity ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher. seekingalpha.com - 1 month ago
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products. zacks.com - 1 month ago
8. Profile Summary

ANI Pharmaceuticals, Inc. ANIP

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.42 B
Dividend Yield 0.03%
Description ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Contact 210 Main Street West, Baudette, MN, 56623 https://www.anipharmaceuticals.com
IPO Date May 5, 2000
Employees 897
Officers Mr. Stephen P. Carey Senior Vice President of Finance & Chief Financial Officer Ms. Meredith W. Cook J.D. Senior Vice President, General Counsel & Corporate Secretary Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease Ms. Krista L. Davis Senior Vice President & Chief Human Resources Officer Dr. Mary Pao M.D., Ph.D. Chief Medical Officer Mr. Ori Gutwerg Senior Vice President of Generics Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, Chief Operating Officer of New Jersey Operations & Director Mr. Christopher K. Mutz Senior Vice President & Head of Rare Disease Mr. Chad Gassert Senior Vice President of Corporate Development & Strategy Mr. Nikhil Lalwani President, Chief Executive Officer & Director